Congenica Co-founder and Scientific Director Dr Matthew Hurles Elected to Fellowship of the Royal Society
Election to the Fellowship of the Royal Society is the highest accolade in UK science and recognises individuals for their scientific excellence and substantial contributions to research endeavours. Dr Hurles has been recognised for his extensive contributions to genetic research notably into the genetic roots of undiagnosed developmental disorders. His work has provided many hundreds of families with clinical diagnoses and laid the foundations of national clinical genetic screening services in the UK and worldwide.
Dr Hurles was one of the founding members that established Congenica in 2014. He has led ground-breaking research projects such as the 1000 Genomes, UK10K and Deciphering Developmental Disorders projects, which have led to a greater understanding of the human genome and the underlying causes of disease. He has pioneered the analysis of exomes to understand genetic disorders that have previously failed diagnostic methods, and his work has directly led to the diagnosis of hundreds of patients with genetic disorders.
The success of the studies has resulted in the launch of the NHS Genomic Medicine Service, for which Congenica is partnered as the exclusive provider of Diagnostic Decision Support Services based on Congenica’s platform SapientiaTM.
Dr Hurles said: “I am honoured to have been elected to this prestigious organisation, this work is a reflection of hundreds of hours of commitment from researchers, clinicians, parents and patients without whom this would not be possible. It is humbling to know that my work has helped so many people, and I believe this is only the beginning for genomic healthcare.”
Dr Hurles will join a group of the most eminent scientists, technologists and engineers from around the world that have made significant contributions to science.
- ENDS -
Notes To Editors
Congenica is the provider of the diagnostic decision support platform, SapientiaTM, and associated clinical services, which enable clinicians to interrogate the human genome to identify disease-causing variants.
80% of rare diseases are thought to have a genetic component, and patients wait an average of 4.7 years, and typically see 7.4 different clinical specialists, before getting a diagnosis. SapientiaTM enables clinicians to progress through workflows more quickly, optimizing throughput of patients, number of patients diagnosed and reducing costs.
Headquartered in Cambridge, UK, and with a footprint in the US and China, Congenica is born out of pioneering research from the Wellcome Trust Sanger Institute and the NHS. Congenica was a partner for the pivotal Genomics England 100,000 Genomes Project and is now the exclusive provider of Diagnostic Decision Support Services for the NHS Genomic Medicine Service.
Issued for and on behalf of Congenica by Instinctif Partners.
For more information please contact:
For media enquiries or to request photos
Sue Charles / Tim Watson
Telephone: +44 (0)20 7866 7861